Compare Stocks: KTTA, FLNA, RNXT, and EXOZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXOZ eXoZymes	$4.65 +1.1%	$7.40	$4.35 ▼ $18.40	$42.37M	2.73	9,459 shs	2,276 shs
FLNA Cassava Sciences	$1.01 +5.2%	$1.21	$0.86 ▼ $4.98	$46.38M	-0.73	333,839 shs	333,244 shs
KTTA Pasithea Therapeutics	$0.46 +3.6%	$0.54	$0.28 ▼ $2.06	$11.07M	0.29	335,548 shs	252,556 shs
RNXT RenovoRx	$0.96 +1.8%	$0.91	$0.70 ▼ $1.45	$42.40M	0.99	187,462 shs	244,982 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXOZ eXoZymes	+1.20%	-1.27%	-45.23%	-52.31%	-53.96%
FLNA Cassava Sciences	+5.21%	+13.37%	-19.20%	-33.11%	-53.24%
KTTA Pasithea Therapeutics	+3.58%	+1.08%	-18.87%	-45.32%	-37.12%
RNXT RenovoRx	+1.82%	+10.75%	+0.32%	+8.49%	-20.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EXOZ eXoZymes	$4.65 +1.1%	$7.40	$4.35 ▼ $18.40	$42.37M	2.73	9,459 shs	2,276 shs
FLNA Cassava Sciences	$1.01 +5.2%	$1.21	$0.86 ▼ $4.98	$46.38M	-0.73	333,839 shs	333,244 shs
KTTA Pasithea Therapeutics	$0.46 +3.6%	$0.54	$0.28 ▼ $2.06	$11.07M	0.29	335,548 shs	252,556 shs
RNXT RenovoRx	$0.96 +1.8%	$0.91	$0.70 ▼ $1.45	$42.40M	0.99	187,462 shs	244,982 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EXOZ eXoZymes	+1.20%	-1.27%	-45.23%	-52.31%	-53.96%
FLNA Cassava Sciences	+5.21%	+13.37%	-19.20%	-33.11%	-53.24%
KTTA Pasithea Therapeutics	+3.58%	+1.08%	-18.87%	-45.32%	-37.12%
RNXT RenovoRx	+1.82%	+10.75%	+0.32%	+8.49%	-20.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EXOZ eXoZymes	1.00	Sell	N/A	N/A
FLNA Cassava Sciences	2.00	Hold	$5.00	395.05% Upside
KTTA Pasithea Therapeutics	2.67	Moderate Buy	$3.00	552.32% Upside
RNXT RenovoRx	2.75	Moderate Buy	$8.50	786.99% Upside

Current Analyst Ratings Breakdown

Latest KTTA, FLNA, RNXT, and EXOZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	FLNA Cassava Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	KTTA Pasithea Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/29/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	KTTA Pasithea Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/16/2026	KTTA Pasithea Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
6/8/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/1/2026	KTTA Pasithea Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
6/1/2026	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.50 ➝ $14.00
5/29/2026	EXOZ eXoZymes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/26/2026	FLNA Cassava Sciences	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EXOZ eXoZymes	$70K	611.81	N/A	N/A	$0.40 per share	11.63
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$2.39 per share	N/A
RNXT RenovoRx	$1.12M	38.55	N/A	N/A	$0.15 per share	6.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EXOZ eXoZymes	-$9.16M	-$1.14	N/A	N/A	N/A	N/A	-220.63%	-141.26%	N/A
FLNA Cassava Sciences	-$90.97M	-$0.87	N/A	N/A	N/A	N/A	-58.78%	-36.74%	N/A
KTTA Pasithea Therapeutics	-$20.43M	-$2.08	N/A	N/A	N/A	N/A	-57.44%	-53.61%	8/13/2026 (Estimated)
RNXT RenovoRx	-$11.17M	-$0.33	N/A	N/A	N/A	-823.98%	-135.03%	-101.92%	8/12/2026 (Estimated)

Latest KTTA, FLNA, RNXT, and EXOZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	N/A	KTTA Pasithea Therapeutics	-$0.16	N/A	N/A	N/A	$0.30 million	N/A
8/12/2026	Q2 2026	RNXT RenovoRx	-$0.08	N/A	N/A	N/A	$0.70 million	N/A
7/29/2026	Q2 2026	FLNA Cassava Sciences	N/A	-$0.18	N/A	-$0.18	N/A	N/A
5/15/2026	Q1 2026	KTTA Pasithea Therapeutics	-$0.45	-$0.12	+$0.33	-$0.12	$0.10 million	N/A
5/14/2026	Q1 2026	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A
5/14/2026	Q1 2026	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.09	$0.47 million	$0.56 million
5/7/2026	Q1 2026	FLNA Cassava Sciences	N/A	-$0.21	N/A	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
FLNA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EXOZ eXoZymes	0.03	1.32	1.32
FLNA Cassava Sciences	N/A	2.08	2.19
KTTA Pasithea Therapeutics	N/A	35.41	35.41
RNXT RenovoRx	N/A	7.15	6.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EXOZ eXoZymes	N/A
FLNA Cassava Sciences	38.05%
KTTA Pasithea Therapeutics	23.92%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
EXOZ eXoZymes	72.41%
FLNA Cassava Sciences	4.60%
KTTA Pasithea Therapeutics	2.00%
RNXT RenovoRx	9.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EXOZ eXoZymes	29	9.21 million	2.54 million	N/A
FLNA Cassava Sciences	20	48.31 million	46.09 million	Optionable
KTTA Pasithea Therapeutics	3	24.94 million	24.44 million	Not Optionable
RNXT RenovoRx	6	45.05 million	40.82 million	Not Optionable

KTTA, FLNA, RNXT, and EXOZ Headlines

Recent News About These Companies

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

July 29 at 8:30 AM | globenewswire.com

RenovoRx Stock Short Interest Report | NASDAQ:RNXT | Benzinga

July 7, 2026 | benzinga.com

RenovoRx Stockholders Approve Directors and Equity Plan

June 30, 2026 | tipranks.com

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

June 23, 2026 | seekingalpha.com

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

June 11, 2026 | globenewswire.com

Ascendiant Remains a Buy on RenovoRx (RNXT)

June 5, 2026 | theglobeandmail.com

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

June 4, 2026 | globenewswire.com

RenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 28, 2026 | finanznachrichten.de

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 28, 2026 | globenewswire.com

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

May 26, 2026 | globenewswire.com

Mark Voll Buys 25,000 Shares of RenovoRx (NASDAQ:RNXT) Stock

May 22, 2026 | insidertrades.com

RenovoRx (RNXT) Q1 2026 Earnings Transcript

May 19, 2026 | fool.com

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

May 19, 2026 | globenewswire.com

Shaun Bagai, CEO of Renovorx, buys $0 of RNXT stock

May 18, 2026 | investing.com

RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion

May 15, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2026 | zacks.com

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

May 14, 2026 | finance.yahoo.com

RenovoRx Inc (RNXT) Q1 2026 Earnings Report Preview: What To Expect

May 14, 2026 | finance.yahoo.com

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

May 7, 2026 | zacks.com

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA)

May 1, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA, FLNA, RNXT, and EXOZ Company Descriptions

eXoZymes NASDAQ:EXOZ

$4.65 +0.05 (+1.09%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.65 0.00 (0.00%)

As of 07/31/2026 04:10 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Cassava Sciences NASDAQ:FLNA

$1.01 +0.05 (+5.21%)

As of 07/31/2026 04:00 PM Eastern

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Pasithea Therapeutics NASDAQ:KTTA

$0.46 +0.02 (+3.58%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.44 -0.02 (-3.89%)

As of 07/31/2026 07:57 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

RenovoRx NASDAQ:RNXT

$0.96 +0.02 (+1.82%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.93 -0.03 (-2.74%)

As of 07/31/2026 06:20 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KTTA, FLNA, RNXT, and EXOZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KTTA, FLNA, RNXT, and EXOZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KTTA, FLNA, RNXT, and EXOZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA, FLNA, RNXT, and EXOZ Company Descriptions

eXoZymes NASDAQ:EXOZ

Cassava Sciences NASDAQ:FLNA

Pasithea Therapeutics NASDAQ:KTTA

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KTTA, FLNA, RNXT, and EXOZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KTTA, FLNA, RNXT, and EXOZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KTTA, FLNA, RNXT, and EXOZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA, FLNA, RNXT, and EXOZ Company Descriptions

eXoZymes NASDAQ:EXOZ

Cassava Sciences NASDAQ:FLNA

Pasithea Therapeutics NASDAQ:KTTA

RenovoRx NASDAQ:RNXT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools